Value of quantitative microsurface structure analysis for evaluating the invasion depth of type 0–II early gastric cancer
JGH Open
by Zhang‐Xiu Jiang, Yun‐Xiao Liang, Peng‐Yu Huang, Jia‐Juan Ning, Jing‐Jing Qi
1d ago
Blue and Green Lines: The ROC curve of EUS, area ratio in predicting M/SM of type 0–II gastric gastric cancer. Yellow line: The ROC curve of DPS in predicting SM1/SM2 of type 0–II gastric gastric cancer. The area ratio has the highest diagnostic accuracy (91.6%). Abstract Background and Aim The microsurface structure reflects the degree of damage to the glands, which is related to the invasion depth of early gastric cancer. To evaluate the diagnostic value of quantitative microsurface structure analysis for estimating the invasion depth of early gastric cancer. Methods White-light imaging an ..read more
Visit website
Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease
JGH Open
by Anke L Nguyen, Claudia Brick, David Liu, David J Gibson, Peter R Gibson, Miles P Sparrow
1d ago
A retrospective study was conducted in patients with inflammatory bowel disease, to investigate the utility of C-reactive protein-to-albumin ratio (CAR) in disease activity monitoring (measured by faecal calprotectin or Mayo Endoscopic Score) and in predicting infliximab trough levels. CAR was only a modest discriminator of subtherapeutic infliximab trough levels and offered little more than C-reactive protein alone in detecting objective active inflammation. Abstract Background and Aim C-reactive protein (CRP)-to-albumin ratio (CAR) is a novel score with prognostic value in inflammatory con ..read more
Visit website
Trends in mortality from gastrointestinal, hepatic, and pancreatic cancers in the United States: A comprehensive analysis (1999–2020)
JGH Open
by Hassam Ali, Rizwan Ishtiaq, Brandon Tedder, Joshua Zweigle, Romina Nomigolzar, Dushyant S Dahiya, Vishali Moond, Amir Humza Sohail, Pratik Patel, Debargha Basuli, Hans L Tillmann
1d ago
From 1999 to 2020, gastrointestinal cancer-related mortality in the United States generally declined, with the age-adjusted mortality rate decreasing from 46.7 to 38.4 per 100,000. Despite this overall reduction, disparities persist with varying rates of decline among different racial groups and increases in mortality for cancers of the small bowel, anus, pancreas, and liver. Significant declines were noted in esophageal, stomach, colon, rectal, and gallbladder cancers, highlighting variations by sex and race. Abstract Background and Aim This study investigates temporal trends in gastrointes ..read more
Visit website
Hypertriglyceridemia‐induced acute necrotizing pancreatitis: Poor clinical outcomes requiring revisiting management modalities
JGH Open
by Yazan Abboud, Meet Shah, Benjamin Simmons, Kranthi Mandava, John E M Morales, Fouad Jaber, Saqer Alsakarneh, Mohamed Ismail, Kaveh Hajifathalian
3d ago
While supportive measures, intravenous insulin, and plasmapheresis are possible treatment modalities for hypertriglyceridemia-induced acute pancreatitis (HGT-AP), definitive guidelines evaluating the best therapeutic approach are not clearly established. We report a 42-year-old male who was found to have HGT-AP and developed necrotizing pancreatitis and subsequent multi-organ failure despite early initiation of intravenous insulin and plasmapheresis. Future studies are warranted to assess risk factors associated with outcomes of HTG-AP, and to evaluate the role of plasmapheresis in HTG-AP and ..read more
Visit website
Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
JGH Open
by Hiroki Ono, Masanori Atsukawa, Akihito Tsubota, Taeang Arai, Kenta Suzuki, Tetsuyuki Higashi, Michika Kitamura, Kaori Shioda‐Koyano, Tadamichi Kawano, Yuji Yoshida, Tomomi Okubo, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Mototsugu Nagao, Masato Iwabu, Katsuhiko Iwakiri
2w ago
This study demonstrated that 48-week pemafibrate administration improved liver-related enzymes and surrogate marker of liver fibrosis in patients with MASLD. Abstract Background and Aim This study aimed to clarify the efficacy and safety of 48-week pemafibrate treatment in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated by dyslipidemia. Methods A total of 110 patients diagnosed with MASLD complicated by dyslipidemia received pemafibrate at a dose of 0.1 mg twice daily for 48 weeks. Results The participants were 54 males and 37 females, with a median ..read more
Visit website
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta‐analysis of randomized controlled trials
JGH Open
by Othman Saleh, Mohamed T. Abuelazm, Islam Mohamed, Alaa Ramadan, Mohammad Assaf, Ahmad Alzoubi, Majd M. AlBarakat, Basel Abdelazeem
2w ago
Abstract Background and Aim Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. However, the evidence of etrolizumab efficacy and safety in ulcerative colitis remains inconclusive. Therefore, we aim to evaluate the safety and efficacy of etrolizumab as an induction and maintenance therapy for active moderate to severe ulcerative colitis. Methods We synthesized randomized controlled studies (RCTs) from MEDLINE, Scopus, EMBASE, PubMed, Web of Science, and Cochrane Library until April 2023. The risk ratio (RR) for dichotomous outcomes with the corresponding 95% confidence interval ..read more
Visit website
Hot avulsion versus argon plasma coagulation for the management of the non‐ensnarable polyp: A multicenter, randomized controlled trial
JGH Open
by Chloe Attree, Ravinder Ogra, Ian F Yusoff, Alan C Moss, Angela Jacques, Gregor Brown, Sina Alexander, Marios Efthymiou, Spiro Raftopoulos
3w ago
This randomised controlled study compared neoplasia eradication using hot avulsion and argon plasma coagulation in colonic polyps when snare polypectomy had failed. The residual adenoma rate at 6 months (hot avulsion 6% vs argon plasma coagulation 21% p = 0.09) and 18 months was not different (6.6 % vs 3.6% p = .25). One patient in the argon plasma coagulation arm was diagnosed with metastatic cancer of likely colorectal origin despite benign histology in the original polypectomy specimen, supporting the importance of tissue acquisition. Abstract Background and Aim Snare resection of nonlift ..read more
Visit website
A systematic review with meta‐analysis: Efficacy and safety of potassium‐competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis
JGH Open
by Daniel M Simadibrata, Elvira Lesmana, Muhammad I A Pratama, Adrianus J Sugiharta, Afiah S Winarizal, Yeong Y Lee, Ari F Syam
3w ago
In comparison to lansoprazole 15 mg, vonoprazan 10 mg and 20 mg resulted in significantly higher maintenance of healed erosive esophagitis. Any treatment-emergent adverse events were greater with vonoprazan 20 mg compared to lansoprazole 15 mg but not vonoprazan 10 mg. Abstract Introduction Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of healed erosive esophagitis (EE). It is unknown whether potassium-competitive acid blockers (PCABs) are more efficacious and safer than PPIs. Methods Only randomized controlled trials (RCTs) comparing PCABs to PPIs in the maintenanc ..read more
Visit website
Antimicrobial therapy outcomes in acute cholangitis: Hilar multiple obstructions versus single hilar and common bile duct obstructions
JGH Open
by Sakue Masuda, Yoshinori Imamura, Ryuhei Jinushi, Jun Kubota, Karen Kimura, Makomo Makazu, Ryo Sato, Makoto Kako, Masahiro Kobayashi, Haruki Uojima, Chikamasa Ichita, Kazuya Koizumi
1M ago
This study evaluates the efficacy of antimicrobial therapy durations recommended by the Tokyo Guidelines 2018 for acute cholangitis (AC), comparing different obstruction etiologies. Results indicate that patients with multiple hilar biliary obstructions (Group 3) experience poorer outcomes compared to those with single obstructions (Groups 1 and 2), suggesting that treatment efficacy is influenced by obstruction complexity, irrespective of the antimicrobial therapy duration. Abstract Background and Aim The appropriate duration of antimicrobial therapy for acute cholangitis (AC) arising from ..read more
Visit website
Efficacy and safety of pinaverium bromide as an add‐on therapy in refractory dyspepsia: A randomized controlled trial
JGH Open
by Thansita Kamolsripat, Nithi Thinrungroj, Kanokwan Pinyopornpanish, Phuripong Kijdamrongthum, Apinya Leerapun, Taned Chitapanarux, Satawat Thongsawat, Ong‐Ard Praisontarangkul, Suwalee Pojchamarnwiputh
1M ago
This randomized, placebo-controlled study investigated the addition of pinaverium bromide to omeprazole for treating refractory functional dyspepsia (FD). Results showed no significant difference between pinaverium bromide and placebo in terms of achieving adequate symptom relief, overall symptom scores, or quality of life improvements. While pinaverium bromide was well-tolerated, the study suggests it provides no additional benefit for managing refractory FD when combined with omeprazole. Abstract Background and Aim Functional dyspepsia (FD) remains a therapeutic challenge, and the efficacy ..read more
Visit website

Follow JGH Open on FeedSpot

Continue with Google
Continue with Apple
OR